Surgical aortic valve replacement with a stented pericardial bioprosthesis: 5-year outcomes.


Journal

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069

Informations de publication

Date de publication:
03 08 2022
Historique:
received: 06 01 2022
revised: 21 04 2022
accepted: 04 07 2022
pubmed: 6 7 2022
medline: 5 8 2022
entrez: 5 7 2022
Statut: ppublish

Résumé

This analysis evaluated the safety, durability and haemodynamic performance of a stented bovine pericardial valve through 5 years of follow-up in patients with an indication for surgical aortic valve replacement. Kaplan-Meier analysis was used to estimate the incidence of survival and valve-related thromboembolism, major paravalvular leak, endocarditis, structural valve deterioration (SVD) and reintervention. The mean aortic gradient and New York Heart Association (NYHA) functional class were also evaluated. A total of 1118 patients have received the Avalus valve; 564 have completed the 5-year follow-up. The median follow-up was 4.85 years (4810 patient-years total follow-up). At baseline, the mean age was 70.2 ± 9.0 years; 75.1% of patients were male. The Society of Thoracic Surgeons predicted risk of mortality was 2.0 ± 1.4%. Most patients were in NYHA functional class II (46.8%) or III (40.3%). At the 5-year follow-up, the overall Kaplan-Meier survival rate was 88.1% (85.9-90.0%). The Kaplan-Meier event rates were 5.6% (4.3-7.2%) for thromboembolism, 4.4% (3.2-6.0%) for endocarditis, 0.2% (0.0-0.7%) for a major paravalvular leak and 3.2% (2.3-4.6%) for reintervention. There were no cases of SVD. The mean gradient decreased from 42.1 ± 17.1 mmHg at baseline, to 13.1 ± 4.7 mmHg at discharge and remained stable at 12.5 ± 4.6 mmHg at 5 years. More than 95% of patients were in NYHA functional class I/II 5 years after surgery. The findings of a high survival rate, excellent safety, no SVD and stable haemodynamic performance and functional status through 5 years of follow-up are encouraging. Additional follow-up is needed to assess the long-term durability of this contemporary surgical bioprosthesis.

Identifiants

pubmed: 35789382
pii: 6631229
doi: 10.1093/ejcts/ezac374
pmc: PMC9346377
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.

Références

Ann Thorac Surg. 2021 Apr;111(4):1198-1205
pubmed: 33011168
Ann Thorac Surg. 2019 May;107(5):1356-1362
pubmed: 30513317
Circulation. 1994 Jul;90(1):323-9
pubmed: 8026014
J Thorac Cardiovasc Surg. 2018 Oct;156(4):1368-1377.e5
pubmed: 29778342
N Engl J Med. 2019 May 2;380(18):1706-1715
pubmed: 30883053
Eur Heart J Cardiovasc Imaging. 2020 Oct 1;21(10):1116-1122
pubmed: 32243493
Eur J Cardiothorac Surg. 2017 Sep 01;52(3):425-431
pubmed: 28475690
Ann Thorac Surg. 2022 Jan 20;:
pubmed: 35065065
J Thorac Cardiovasc Surg. 2006 Nov;132(5):1137-43
pubmed: 17059935
Eur J Cardiothorac Surg. 2021 Jan 29;59(2):434-441
pubmed: 33141188
J Am Coll Cardiol. 2019 Feb 12;73(5):546-553
pubmed: 30732707
J Thorac Cardiovasc Surg. 2019 Nov 2;:
pubmed: 31864696
Circulation. 2019 Feb 1;:
pubmed: 30704298
Ann Thorac Surg. 2021 Nov;112(5):1424-1431
pubmed: 33338482
J Am Coll Cardiol. 2020 Nov 24;76(21):2492-2516
pubmed: 33213729
J Thorac Cardiovasc Surg. 2017 Mar;153(3):561-569.e2
pubmed: 27964975
J Thorac Cardiovasc Surg. 2020 Nov 12;:
pubmed: 33339597
J Thorac Cardiovasc Surg. 2020 Aug;160(2):371-381.e4
pubmed: 31590957
J Thorac Cardiovasc Surg. 2021 Aug 31;:
pubmed: 34538638
J Am Coll Cardiol. 2021 Jun 1;77(21):2717-2746
pubmed: 33888385
Ann Thorac Surg. 2001 Jan;71(1):92-9
pubmed: 11216817
Eur J Cardiothorac Surg. 2008 Apr;33(4):523-8
pubmed: 18313319
J Thorac Cardiovasc Surg. 2021 Jul 20;:
pubmed: 34364682
J Thorac Cardiovasc Surg. 2021 Nov;162(5):1478-1485
pubmed: 32340804
JACC Cardiovasc Interv. 2019 May 27;12(10):923-932
pubmed: 31122349
N Engl J Med. 2017 Apr 6;376(14):1321-1331
pubmed: 28304219

Auteurs

Robert J M Klautz (RJM)

Department of Cardiothoracic Surgery, Leiden University Medical Center, Leiden, Netherlands.

François Dagenais (F)

Division of Cardiac Surgery, Quebec Heart and Lung Institute, Quebec, QC, Canada.

Michael J Reardon (MJ)

Department of Cardiovascular Surgery, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.

Rüdiger Lange (R)

Department of Cardiovascular Surgery, German Heart Centre Munich, Munich, Germany.

Michael G Moront (MG)

Department of Cardiothoracic Surgery, ProMedica Toledo Hospital, Toledo, OH, USA.

Louis Labrousse (L)

Medico-Surgical Department of Valvulopathies, Bordeaux Heart University Hospital, Bordeaux-Pessac, France.

Neil J Weissman (NJ)

MedStar Health Research Institute, MedStar Health, Washington, DC, USA.

Vivek Rao (V)

Department of Surgery, Toronto General Hospital, Toronto, ON, Canada.

Himanshu J Patel (HJ)

Department of Cardiac Surgery, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, USA.

Fang Liu (F)

Cardiac Surgery Clinical Research and Medical Science, Medtronic, Mounds View, MN, USA.

Joseph F Sabik (JF)

Department of Surgery, University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH